The FDA advisory committee voted against a specific dosage for a GSK drug, leading to negative market sentiment affecting companies including Humana and Sarepta Therapeutics.
21 reports, 4 independent
Updated Aug 5
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 21
- Developments
- 5
- Repetition
- 76%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA advisory committee voted against a specific dosage for a GSK drug, leading to negative market sentiment affecting companies including Humana and Sarepta Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA advisory committee voted against GSK drug dosage, impacting multiple companies.1 source
FDA cleared Sarepta's therapy after investigation, sparking commentary on gene therapy promise.1 source
New developments include a lost Medicare lawsuit and a patient death tied to experimental gene therapy.1 source
New developments include a lost Medicare lawsuit and a reported patient death from gene therapy.1 source
FDA vote against GSK dosage is compounded by gene therapy patient death and managed care provider weaknesses.1 source
Keep exploring
The entities involved
- FDA
-
GSK
British multinational pharmaceutical and biotechnology company
-
Humana
American managed health care company
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
Related events
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
Coverage
Newest first; wire copies grouped- StockStoryWhy Is Privia Health (PRVA) Stock Soaring Today Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 6.4% in the morning session after the company announced its Accountable Care
- Pharmaceutical TechnologyCell and gene therapies on correction course but not sinking When the first gene therapy using CRISPR was approved in the US in 2023, former President Joe Biden struck an optimistic tone. “This holds
- StockStoryWhy Astrana Health (ASTH) Stock Is Trading Up Today Shares of healthcare services company Astrana Health jumped 34.2% in the morning session after the company reported better-than-expected second-qua
- StockStoryWhy LifeStance Health Group (LFST) Stock Is Up Today Shares of behavioral health company LifeStance Health (NASDAQ:LFST) jumped 11% in the afternoon session after the company reported mixed second-qu
- StockStoryWhy Lantheus (LNTH) Stock Is Falling Today Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell 29.8% in the afternoon session after the company reported disappointing second-qu
- StockStoryWhy Supernus Pharmaceuticals (SUPN) Stock Is Up Today Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 3.1% in the morning session after Cantor Fitzgerald upgr
- StockStoryWhy Revvity (RVTY) Stock Is Falling Today Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its full-year profit forecast, which oversha
- StockStoryWhy Centene (CNC) Stock Is Trading Up Today Shares of health coverage company Centene (NYSE:CNC) jumped 5.9% in the afternoon session after the company reported second-quarter results that missed ear
- StockStoryWhy Integer Holdings (ITGR) Stock Is Down Today Shares of medical technology company Integer Holdings (NYSE:ITGR) fell 8.3% in the afternoon session after the company reported second-quarter results
- StockStoryWhy Are West Pharmaceutical Services (WST) Shares Soaring Today Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the company r
- StockStoryWhy Privia Health (PRVA) Stock Is Up Today Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors anticipated a heavy week of corporate ea
- StockStoryBiogen (BIIB) Stock Trades Down, Here Is Why Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist downgraded the stock, citing concerns over the co
- StockStoryThermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know A number of healthcare stocks fell in the afternoon session after several negative
- StockStoryModerna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know A number of healthcare stocks fell in the afternoon session after several negative developme
- StockStoryEvolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know A number of healthcare stocks fell in the afternoon
- StockStoryQuidelOrtho, Acadia Healthcare, Elevance Health, Molina Healthcare, and Alignment Healthcare Stocks Trade Down, What You Need To Know A number of healthcare stocks fell in the afternoon session after
- StockStoryEnovis, CONMED, Astrana Health, Privia Health, and Waters Corporation Stocks Trade Down, What You Need To Know A number of healthcare stocks fell in the afternoon session after several negative devel
- BenzingaGSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefi
- ZacksFDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of t